Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current Status and Perspectives of Therapeutic Antibodies Targeting the Spike Protein S2 Subunit against SARS-CoV-2

30 Apr 2024

Abstract excerpt

The global coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has devastated public health and the global economy. New variants are continually emerging because of amino acid mutations within the SARS-CoV-2 spike protein. Existing neutralizing antibodies (nAbs) that target the receptor-binding domain (RBD) within the spike protein have been shown...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research
Share to Transgenic Plants and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38692869
DOI: 10.1248/bpb.b23-00639

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current Status and Perspectives of Therapeutic Antibodies Targeting the Spike Protein S2 Subunit against SARS-CoV-2PMID 38692869Read ↗

SARS-CoV-2 spike S2-specific neutralizing antibodiesSemantic proximity Read ↗

Structural Insights into the SARS-CoV-2 Spike Protein and Its Implications for Antibody Resistance.Semantic proximity Read ↗

The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 PandemicSemantic proximity Read ↗

Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronavirusesSemantic proximity Read ↗

Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variantsSemantic proximity Read ↗

Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.Semantic proximity Read ↗

Neutralizing antibodies targeting SARS-CoV-2 spike proteinSemantic proximity Read ↗

Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronavirusesSemantic proximity Read ↗

Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2Semantic proximity Read ↗

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its baseSemantic proximity Read ↗

Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane FusionSemantic proximity Read ↗

Broadly neutralizing antibodies against COVID-19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.